title: Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.
abstract: We analyzed the biodistribution of the 111In-labelled murine anti-tenascin-C MAb BC-2 after intralesional injection in 15 glioblastoma patients. The activated ligand DTPA was conjugated via the isothiocyanato-benzyl group onto BC-2. Conjugates were labelled with 111In, displaying immunoreactivity greater than 90% and labelling efficiency of 99 +/- 1%. In contrast to i.v. injections, excellent tumor uptake was obtained by direct intralesional injection of conjugates that showed only slow systemic release. In serum, conjugates were found to be intact; in urine, only low-molecular-weight decay products were detected. In 8 patients, outflow from the site of injection into systemic circulation was low; daily activity in the serum and urine was found to be below 2% of the total injected radioactivity; most of the injected activity was retained within the tumor, resulting in effective half-lives of 58 +/- 5 hr. In contrast, higher outflow up to 10% of regionally injected 111In-DTPA-BC-2 MAb into systemic circulation resulted in considerable shortening of the effective half-lives to 20 to 40 hr in 7 patients. This outflow was found to correlate with tumor size and blood/brain barrier disruption. In one patient, HPLC analysis of tumor cyst fluid 3 and 6 days after intralesional injection revealed conjugates to be intact and allowed the estimate of about 70% of the total injected 111In-DTPA-BC-2 to be confined to tumor tissue. We conclude that different outflow patterns can be observed following locoregional injection of 111In-DTPA-BC-2, leading to considerable variations in the effective half-lives of isotopes within the tumor, requiring adjustment of the radiation dose in therapeutic trials.
authors.affiliation: Neurosurgery, University Hospitals, Basel, Switzerland. merlo@ubaclu.unibas.ch
authors.forename: A
authors.initials: A
authors.lastname: Merlo
authors.forename: E
authors.initials: E
authors.lastname: Jermann
authors.forename: O
authors.initials: O
authors.lastname: Hausmann
authors.forename: R
authors.initials: R
authors.lastname: Chiquet-Ehrismann
authors.forename: A
authors.initials: A
authors.lastname: Probst
authors.forename: H
authors.initials: H
authors.lastname: Landolt
authors.forename: H R
authors.initials: HR
authors.lastname: Maecke
authors.forename: J
authors.initials: J
authors.lastname: Mueller-Brand
authors.forename: O
authors.initials: O
authors.lastname: Gratzl
mesh_terms: D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001932:Brain Neoplasms / Q000378:metabolism*; D005260:Female; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D007205:Indium Radioisotopes; D007700:Kinetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D019063:Tenascin / Q000276:immunology*; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D019063:Tenascin